IART - IART 6-DAY DEADLINE ALERT: Hagens Berman National Trial Attorneys Encourages Integra LifeSciences (IART) Investors with Substantial Losses to Contact the Firm Before Nov. 13th Deadline in Securities Fraud Class Action | Benzinga

SAN FRANCISCO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Integra LifeSciences Holdings Corp. (NASDAQ:IART) investors who suffered substantial losses to submit your losses now.

Class Period: Mar. 11, 2019 – May 22, 2023
Lead Plaintiff Deadline: Nov. 13, 2023
Visit: www.hbsslaw.com/investor-fraud/IART
Contact An Attorney Now: IART@hbsslaw.com
844-916-0895

Integra LifeSciences Holdings Corp. (IART) Securities Fraud Class Action:

The litigation focuses on Integra's disclosures related to the FDA's findings of Good Manufacturing Practices violations at its Boston Facility.

The complaint alleges that Integra made false and misleading statements and failed to disclose that: (1) Integra failed to take sufficient measures to remediate violations identified by the FDA; (2) as a result of those deficiencies, all products manufactured in the Boston Facility since March 2018 had the potential for higher-than-permitted levels of bacterial endotoxins and would need to be recalled; and (3) the company was not making progress toward obtaining its pre-market approval ("PMA") indication for SurgiMend (one of Integra's principal wound ...

IART) Investors with Substantial Losses to Contact the Firm Before Nov. 13th Deadline in Securities Fraud Class Action>Full story available on Benzinga.com